These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 16838658)

  • 1. [Devices for the safe performance of self-injection of interferon therapy for chronic hepatitis C].
    Kurihara T; Mikata R; Yokosuka O
    Nihon Rinsho; 2006 Jul; 64(7):1368-73. PubMed ID: 16838658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].
    MMW Fortschr Med; 2002 Sep; 144(38):59. PubMed ID: 12395712
    [No Abstract]   [Full Text] [Related]  

  • 3. Cutaneous necrosis complicating the injection of pegylated interferon alpha-2b in a patient with chronic hepatitis C.
    Rosina P; Girolomoni G
    Acta Dermatovenerol Croat; 2008; 16(1):35-7. PubMed ID: 18358108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin.
    Onyike CU; Bonner JO; Lyketsos CG; Treisman GJ
    Am J Psychiatry; 2004 Mar; 161(3):429-35. PubMed ID: 14992966
    [No Abstract]   [Full Text] [Related]  

  • 5. Injection site with generalized rash caused by pegylated interferon alpha 2a injection.
    Kawada K; Maeda N; Kobayashi S; Sowa J; Tsuruta D; Kawada N
    Dermatology; 2006; 212(1):82-3. PubMed ID: 16319482
    [No Abstract]   [Full Text] [Related]  

  • 6. [Side effect of pegylated-interferon treatment in chronic C hepatitis: agranulocytosis].
    Halász T; Farkas A; Tolvaj G; Horváth G
    Orv Hetil; 2006 Feb; 147(7):321-4. PubMed ID: 17489160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antiviral therapy for chronic viral hepatitis B and C].
    Iino S
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():787-91. PubMed ID: 12722317
    [No Abstract]   [Full Text] [Related]  

  • 8. Bullous lesions at polyethylene glycol interferon-alpha-2a inoculation site in a hepatitis C virus-infected subject.
    Montesu MA; Siddi V; Satta R; Pirodda C; Cottoni F
    Acta Derm Venereol; 2007; 87(5):433-4. PubMed ID: 17721655
    [No Abstract]   [Full Text] [Related]  

  • 9. [Hepatitis C therapy is not pleasant. Patients must be prepared!].
    MMW Fortschr Med; 2003 Jan; 145(3-4):57. PubMed ID: 12619237
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment strategy for chronic hepatitis C in Japan].
    Arase Y; Kumada H
    Nihon Rinsho; 2011 May; 69 Suppl 4():180-4. PubMed ID: 22096915
    [No Abstract]   [Full Text] [Related]  

  • 12. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus.
    Hashimoto Y; Kanto H; Itoh M
    J Dermatol; 2007 Aug; 34(8):577-82. PubMed ID: 17683392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Difficult-to-treat patients with chronic hepatitis C].
    Zeuzem S
    Praxis (Bern 1994); 2006 Sep; 95(38):1459-64. PubMed ID: 17058596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pulmonary toxicity by pegylated interferon alpha-2a in a patient with chronic hepatitis C].
    Son BK; Sohn JH; Kim TY; Park YK; Jeon YC; Han DS
    Korean J Hepatol; 2007 Mar; 13(1):103-7. PubMed ID: 17380081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hepatitis C infection. Overweight virus carriers are more difficult to cure].
    MMW Fortschr Med; 2004 Mar; 146(13):58. PubMed ID: 15219135
    [No Abstract]   [Full Text] [Related]  

  • 16. [Pegylated interferon plus ribavirin in chronic hepatitis C. More than half of patients show a lasting response].
    Zeuzem S
    MMW Fortschr Med; 2002 Feb; 144(8):30-4. PubMed ID: 11910820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
    Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
    Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases].
    Lopukhova NL
    Eksp Klin Gastroenterol; 2007; (4):146-52. PubMed ID: 18409502
    [No Abstract]   [Full Text] [Related]  

  • 19. Patient education and treatment strategies implemented at a pharmacist-managed hepatitis C virus clinic.
    Kolor B
    Pharmacotherapy; 2005 Sep; 25(9):1230-41. PubMed ID: 16164396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progress in the treatment of hepatitis B and C co-infection in HIV patients].
    Mauss S
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():27-9. PubMed ID: 15373041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.